- Home
- AVPT vs RARE Comparison
AVPT vs RARE Comparison
Compare AVPT & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVPT
- RARE
- Stock Information
- Founded
- AVPT 2001
- RARE 2010
- Country
- AVPT United States
- RARE United States
- Employees
- AVPT N/A
- RARE N/A
- Industry
- AVPT Computer Software: Prepackaged Software
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- AVPT Technology
- RARE Health Care
- Exchange
- AVPT Nasdaq
- RARE Nasdaq
- Market Cap
- AVPT 3.8B
- RARE 3.2B
- IPO Year
- AVPT N/A
- RARE 2014
- Fundamental
- Price
- AVPT $11.99
- RARE $30.62
- Analyst Decision
- AVPT Buy
- RARE Strong Buy
- Analyst Count
- AVPT 8
- RARE 15
- Target Price
- AVPT $18.38
- RARE $87.00
- AVG Volume (30 Days)
- AVPT 1.2M
- RARE 1.4M
- Earning Date
- AVPT 11-06-2025
- RARE 11-04-2025
- Dividend Yield
- AVPT N/A
- RARE N/A
- EPS Growth
- AVPT N/A
- RARE N/A
- EPS
- AVPT 0.01
- RARE N/A
- Revenue
- AVPT $393,993,000.00
- RARE $630,598,000.00
- Revenue This Year
- AVPT $26.20
- RARE $19.65
- Revenue Next Year
- AVPT $18.17
- RARE $23.65
- P/E Ratio
- AVPT $1,537.29
- RARE N/A
- Revenue Growth
- AVPT 24.71
- RARE 20.63
- 52 Week Low
- AVPT $11.50
- RARE $25.81
- 52 Week High
- AVPT $20.25
- RARE $53.04
- Technical
- Relative Strength Index (RSI)
- AVPT 24.92
- RARE 40.07
- Support Level
- AVPT $13.72
- RARE $28.58
- Resistance Level
- AVPT $14.60
- RARE $35.95
- Average True Range (ATR)
- AVPT 0.53
- RARE 1.51
- MACD
- AVPT -0.14
- RARE -0.52
- Stochastic Oscillator
- AVPT 13.97
- RARE 27.68
About AVPT AvePoint Inc.
AvePoint Inc provides customizable solutions to optimize SaaS operations, enable secure collaboration, and accelerate digital transformation across technologies and industries. Its Confidence Platform delivers a comprehensive set of cloud-based solutions enabling IT operations, development operations, and cybersecurity professionals to monitor and secure the digital workplace using SaaS tools.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.